Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression

Prostate cancer (PCa) is the second leading cause of cancer death in men in America, and there are no curative options for metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (DTX) has been used as a standard chemotherapy for the mCRPC. However, resistance to DTX is a significant clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Linyi, Sun, Yin, Luo, Jie, He, Xiang, Ye, Meihua, Li, Gonghui, Zhang, Yong, Bai, Jian, Zhang, Dahong, Chang, Chawnshang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044111/
https://www.ncbi.nlm.nih.gov/pubmed/31748715
http://dx.doi.org/10.1038/s41388-019-1070-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044111/
https://www.ncbi.nlm.nih.gov/pubmed/31748715
http://dx.doi.org/10.1038/s41388-019-1070-5

Ejemplares similares